-
Mashup Score: 0China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC - 1 month(s) ago
China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC - 1 month(s) ago
China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC - 1 month(s) ago
Adding durvalumab to concurrent chemoradiation did not improve survival or safety in patients with unresectable stage III non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC - 1 month(s) ago
Adding durvalumab to concurrent chemoradiation did not improve survival or safety in patients with unresectable stage III non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Exploratory Analysis Shows Perioperative Nivolumab Confers Benefit in Resectable NSCLC, Irrespective of Neoadjuvant Treatment Cycles - 1 month(s) ago
Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC - 1 month(s) ago
China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC @myesmo @IASLC #ELCC24 #lcsm https://t.co/6wZPErWqQ8